Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.
Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.
<iframe src="https://hindustansphere.com/embed/cluster/2cbdd24653f7e19eea5b160b6959d7935c1919e5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million"></iframe>
The shares of Zydus Lifesciences declined 2% to Rs 1,058 on the BSE on Wednesday after the company announced that it has completed the acquisition of US-based pharma company Assertio Holdings Inc. for $166.4 million.In an exchange filing released on Tuesday, Zydus Lifesciences said that it has successfully completed the cash tender offer through its wholly-owned subsidiary, Zara Merger Sub Inc, for all the outstanding shares of common stock of Assertio Holdings Inc.Following the acquisition, As…
